Octreotide-Resistant Acromegaly: Challenges and Solutions.
acromegaly
biochemical control
medical therapy
resistance
somatostatin receptor ligands
Journal
Therapeutics and clinical risk management
ISSN: 1176-6336
Titre abrégé: Ther Clin Risk Manag
Pays: New Zealand
ID NLM: 101253281
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
01
2020
accepted:
10
03
2020
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
23
5
2020
Statut:
epublish
Résumé
Acromegaly is a rare and severe disease caused by an increased and autonomous secretion of growth hormone (GH), thus resulting in high circulating levels of insulin-like growth factor 1 (IGF-1). Comorbidities and mortality rate are closely related to the disease duration. However, in most cases achieving biochemical control means reducing or even normalizing mortality and restoring normal life expectancy. Current treatment for acromegaly includes neurosurgery, radiotherapy and medical therapy. Transsphenoidal surgery often represents the recommended first-line treatment. First-generation somatostatin receptor ligands (SRLs) are the drug of choice in patients with persistent disease after surgery and are suggested as first-line treatment for those ineligible for surgery. However, only about half of patients treated with octreotide (or lanreotide) achieve biochemical control. Other available drugs approved for clinical use are the second-generation SRL pasireotide, the dopamine agonist cabergoline, and the GH-receptor antagonist pegvisomant. In the present paper, we revised the current literature about the management of acromegaly, aiming to highlight the most relevant and recent therapeutic strategies proposed for patients resistant to first-line medical therapy. Furthermore, we discussed the potential molecular mechanisms involved in the variable response to first-generation SRLs. Due to the availability of different medical therapies, the choice for the most appropriate drug can be currently based also on the peculiar clinical characteristics of each patient.
Identifiants
pubmed: 32440136
doi: 10.2147/TCRM.S183360
pii: 183360
pmc: PMC7211320
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
379-391Informations de copyright
© 2020 Corica et al.
Déclaration de conflit d'intérêts
DF has been a speaker for, participated on advisory boards and received research grants from Novartis, Pfizer and Ipsen. FG has been a speaker for Novartis, participated on advisory boards and/or received personal fees from Novartis, AMCo Ltd and IONIS Pharmaceuticals. The other authors report no conflicts of interest in this work.
Références
J Neurosurg. 1996 Aug;85(2):239-47
pubmed: 8755752
Endocrinology. 2013 Dec;154(12):4715-25
pubmed: 24169548
J Clin Endocrinol Metab. 2011 May;96(5):1327-35
pubmed: 21325455
J Clin Endocrinol Metab. 2007 Dec;92(12):4598-601
pubmed: 17895318
PLoS One. 2013 Apr 25;8(4):e61523
pubmed: 23634209
Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68
pubmed: 17465997
Mol Endocrinol. 2008 Oct;22(10):2278-92
pubmed: 18653781
Nat Rev Endocrinol. 2018 Sep;14(9):552-561
pubmed: 30050156
J Endocrinol Invest. 2006 Oct;29(9):826-30
pubmed: 17114915
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
J Clin Endocrinol Metab. 2008 Apr;93(4):1412-7
pubmed: 18211974
Endocrinology. 2014 Aug;155(8):2932-41
pubmed: 24828612
J Clin Endocrinol Metab. 2012 Aug;97(8):E1411-20
pubmed: 22659247
J Clin Endocrinol Metab. 2004 Apr;89(4):1577-85
pubmed: 15070915
J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73
pubmed: 15886238
Eur J Endocrinol. 2011 Mar;164(3):325-33
pubmed: 21148630
Neurosurg Clin N Am. 2012 Oct;23(4):621-38
pubmed: 23040748
Pituitary. 2011 Sep;14(3):253-8
pubmed: 21221818
Trends Endocrinol Metab. 2013 May;24(5):238-46
pubmed: 23270713
Clin Endocrinol (Oxf). 2008 Aug;69(2):299-305
pubmed: 18248639
Eur J Endocrinol. 2007 Nov;157(5):579-87
pubmed: 17984237
J Endocrinol Invest. 2017 Jun;40(6):577-589
pubmed: 28176221
Pituitary. 2011 Sep;14(3):284-94
pubmed: 21597975
Endocrinol Metab Clin North Am. 2015 Mar;44(1):89-97
pubmed: 25732645
Endocrine. 2016 Mar;51(3):524-33
pubmed: 25982150
J Clin Endocrinol Metab. 2012 May;97(5):1589-97
pubmed: 22362824
Clin Endocrinol (Oxf). 2012 Jan;76(1):96-102
pubmed: 21722151
J Endocrinol Invest. 2018 May;41(5):575-581
pubmed: 29080965
J Clin Endocrinol Metab. 2010 May;95(5):2497-502
pubmed: 20233783
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2892-2902
pubmed: 30869797
J Clin Invest. 2009 Nov;119(11):3189-202
pubmed: 19884662
Pituitary. 2017 Feb;20(1):121-128
pubmed: 28025719
Endocr J. 2013;60(5):651-63
pubmed: 23337477
Pituitary. 2010;13(1):60-7
pubmed: 19189218
Pituitary. 2015 Dec;18(6):916-23
pubmed: 26224528
Rev Endocr Metab Disord. 2008 Mar;9(1):59-65
pubmed: 18080837
Trends Endocrinol Metab. 2010 Jul;21(7):419-27
pubmed: 20570174
J Exp Clin Cancer Res. 2013 Jun 21;32:40
pubmed: 23799893
Pituitary. 2013 Mar;16(1):101-8
pubmed: 22396133
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2454-2464
pubmed: 28419317
Endocr Rev. 2011 Apr;32(2):247-71
pubmed: 21123741
Clin Chem. 2011 Apr;57(4):555-9
pubmed: 21285256
Endocrine. 2016 Jul;53(1):210-9
pubmed: 26906713
Pituitary. 2017 Feb;20(1):33-45
pubmed: 28168377
Endocr Relat Cancer. 2016 Nov;23(11):871-881
pubmed: 27649724
Mol Endocrinol. 2010 Feb;24(2):436-46
pubmed: 20051480
J Mol Endocrinol. 2013 Dec 19;52(1):R67-77
pubmed: 24049068
Drugs. 2003;63(22):2473-99
pubmed: 14609359
Endocr J. 2012;59(3):221-8
pubmed: 22200580
J Clin Pharmacol. 2005 Jul;45(7):836-44
pubmed: 15951474
Eur J Endocrinol. 2013 Sep 12;169(4):391-400
pubmed: 23847328
Neurosurgery. 2010 Oct;67(4):949-56
pubmed: 20881560
J Clin Endocrinol Metab. 1998 May;83(5):1604-10
pubmed: 9589663
Rev Endocr Metab Disord. 2019 Sep;20(3):365-381
pubmed: 31342434
Clin Endocrinol (Oxf). 2010 Feb;72(2):203-8
pubmed: 19473180
Endocr Pract. 2015 Aug;21(8):943-56
pubmed: 26247235
Endocrinology. 2018 Aug 1;159(8):2953-2965
pubmed: 29931263
Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84
pubmed: 25260838
J Endocrinol. 2016 Nov;231(2):135-145
pubmed: 27587848
J Clin Endocrinol Metab. 2011 Aug;96(8):2405-13
pubmed: 21632808
Nat Rev Endocrinol. 2014 Apr;10(4):243-8
pubmed: 24566817
Eur J Endocrinol. 2018 Dec 1;179(6):419-427
pubmed: 30325178
Endocr Relat Cancer. 2011 Dec 01;18(6):R233-51
pubmed: 22135243
J Cell Mol Med. 2018 Apr;22(4):2110-2116
pubmed: 29377493
Pituitary. 1999 Jun;2(1):29-41
pubmed: 11081170
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9
pubmed: 24423324
Endocr Relat Cancer. 2012 May 24;19(3):L25-9
pubmed: 22420004
Eur J Endocrinol. 2008 Mar;158(3):295-303
pubmed: 18299461
Pituitary. 2013 Dec;16(4):490-8
pubmed: 23184260
J Clin Endocrinol Metab. 2013 Jan;98(1):E66-71
pubmed: 23118420
Pituitary. 2007;10(2):121-8
pubmed: 17429590
Eur J Endocrinol. 2009 Aug;161(2):331-8
pubmed: 19465485
Pituitary. 2017 Feb;20(1):109-115
pubmed: 27778296
Eur J Endocrinol. 2018 Aug 3;179(5):269-277
pubmed: 30076159
Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74
pubmed: 17977644
Pituitary. 2013 Dec;16(4):459-64
pubmed: 23307479
Neurosurgery. 2017 Aug 1;81(2):357-366
pubmed: 28368500
Pituitary. 2011 Jun;14(2):184-93
pubmed: 21161602
J Clin Endocrinol Metab. 2008 Aug;93(8):2957-68
pubmed: 18477663
Eur J Endocrinol. 2005 Aug;153(2):187-93
pubmed: 16061822
PLoS One. 2012;7(5):e36411
pubmed: 22574156
Endocr Pathol. 2008 Summer;19(2):82-91
pubmed: 18629656
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2009-2018
pubmed: 28323931
Eur J Endocrinol. 2008 Aug;159(2):89-95
pubmed: 18524797
Neurosurgery. 2019 Mar 1;84(3):717-725
pubmed: 29757421
J Endocrinol Invest. 2013 Jan;36(1):38-43
pubmed: 22472799
J Clin Neurosci. 2011 Feb;18(2):181-90
pubmed: 21167718
J Clin Endocrinol Metab. 2009 Jul;94(7):2634-43
pubmed: 19401364
J Cell Mol Med. 2019 May;23(5):3088-3096
pubmed: 30843342
J Clin Endocrinol Metab. 2019 Jun 1;104(6):1978-1988
pubmed: 30608534
J Mol Endocrinol. 2014 Jun;52(3):R223-40
pubmed: 24647046
J Clin Endocrinol Metab. 2012 Apr;97(4):1187-93
pubmed: 22278424
Pituitary. 2010;13(1):18-28
pubmed: 19639415
World Neurosurg. 2018 Feb;110:e534-e545
pubmed: 29155347
Endocrine. 2018 Sep;61(3):533-541
pubmed: 29797214
Clin Endocrinol (Oxf). 2012 Jul;77(1):72-8
pubmed: 22066905
J Neurosurg. 2018 Aug;129(2):404-416
pubmed: 28862548
Biologics. 2008 Sep;2(3):463-79
pubmed: 19707377
Metabolism. 1996 Aug;45(8 Suppl 1):67-71
pubmed: 8769387
Sci Rep. 2019 Feb 4;9(1):1122
pubmed: 30718563
Drugs. 2015 Jun;75(9):1039-48
pubmed: 26017304
Endocr J. 2003 Oct;50(5):635-42
pubmed: 14614221
Int J Mol Sci. 2019 Aug 13;20(16):
pubmed: 31412614
Eur J Endocrinol. 2005 Mar;152(3):379-87
pubmed: 15757854
Clin Endocrinol (Oxf). 2007 Jul;67(1):65-70
pubmed: 17437512
J Clin Endocrinol Metab. 2018 Feb 1;103(2):586-595
pubmed: 29155991
Endocr Pract. 2015 Mar;21(3):264-74
pubmed: 25370326
Pituitary. 2016 Aug;19(4):448-57
pubmed: 27279011
J Clin Endocrinol Metab. 2008 Apr;93(4):1254-62
pubmed: 18171702
Pituitary. 2017 Feb;20(1):100-108
pubmed: 28176162
Endocrine. 2018 Nov;62(2):448-455
pubmed: 30051198
Pituitary. 2012 Sep;15(3):398-404
pubmed: 21863263
Neurosurgery. 1998 May;42(5):1013-21; discussion 1021-2
pubmed: 9588545
Eur J Endocrinol. 2017 Apr;176(4):421-431
pubmed: 28100630
J Clin Endocrinol Metab. 2014 May;99(5):1825-33
pubmed: 24606084
Patient Prefer Adherence. 2016 Jul 13;10:1217-25
pubmed: 27471378
Clin Endocrinol (Oxf). 2009 Oct;71(4):549-57
pubmed: 19438906
N Engl J Med. 2006 Dec 14;355(24):2558-73
pubmed: 17167139
Eur J Endocrinol. 2016 May;174(5):651-62
pubmed: 26888629
J Clin Endocrinol Metab. 2014 Oct;99(10):3644-52
pubmed: 24937542
J Clin Endocrinol Metab. 2010 May;95(5):2334-42
pubmed: 20335450
Neuroendocrinology. 2019 Oct 1;:
pubmed: 31574507
Pituitary. 2016 Jun;19(3):235-47
pubmed: 26519143
J Clin Endocrinol Metab. 2012 Apr;97(4):E663-70
pubmed: 22319033
Eur J Endocrinol. 1995 Aug;133(2):147-8
pubmed: 7655637
Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82
pubmed: 19650784
Endocrine. 2015 Feb;48(1):334-41
pubmed: 25150035